| abstract |
(57) [Summary] The present invention relates to a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof for the treatment of a PKC-mediated disease, wherein the compound of formula (I) or formula (II) is Is the formula: [Wherein R 1 is hydrogen, lower alkyl or optionally substituted aryl; R 2 is hydrogen or lower alkyl; R 3 is hydrogen or — (CH 2 ) kR 6 ( Here, R 6 is —CO 2 R 7 , —NHC (O) R 7 , —NR 7 R 8 or —C (O) NR 7 R 8 (wherein R 7 and R 8 are independently hydrogen. or alkyl (provided that when R 6 is -CO 2 R 7, R 7 is a is a group other than hydrogen) be); or R 4 and R 5 are independently from each other hydrogen or lower alkyl Or R 4 and R 5 together with the nitrogen to which they are attached form a saturated or unsaturated 5, 6 or 7 membered ring; E is CH—R 9 (wherein R 9 is hydrogen, alkoxy, —OH or —NR 10 R 11 (wherein R 10 and R 11 independently of one another are hydrogen or lower alkyl). Or R 10 and R 11 together with the nitrogen to which they are attached form a saturated or unsaturated 5, 6 or 7 membered ring)); X is CH or N; Y is -CH 2 or -O, further Y on the central aromatic ring, there respect amine-containing side chain ortho to one of the positions meta or para; Z is substituted by -CH 2 or desired Optionally aryl; k is an integer between 0 and 10; m is an integer between 0 and 10 where Z is optionally substituted aryl or optionally substituted. M is 0 only when it is optionally heteroaryl, and when m is 0 and Z is an optionally substituted aryl or an optionally substituted heteroaryl. 4, and R 5 is hydrogen or Is a group other than lower alkyl); n is an integer between 6 and 20; p is an integer between 0 and 1; provided that Z is an optionally substituted aryl or optionally When it is an optionally substituted heteroaryl, p must be 0]. |